An interventional study of Electroacupuncture (EA) and Sham Electroacupuncture (SEA) in Generalized Anxiety Disorder, sponsored by Lishu Gao. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Lishu Gao · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Generalized Anxiety Disorder with a site in China — 17 open to participants now, 17 under way, 3 of them phase 3. Generalized Anxiety Disorder · China.
Among the 24 studies in Generalized Anxiety Disorder with a site in China, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 9 that started in 2026, is one of 12 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 17th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →17 of the 24 studies in Generalized Anxiety Disorder with a site in China are open now. Recruiting first, the newest first:
Central South University · Sites in China
Ages 18–55
Central South University · Sites in China
Ages 18–65
Fudan University · Sites in China
Ages 18–70 · Women only
Anhui Medical University · Sites in China
Ages 18+
WANG KAI · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 123 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 120 across the 21 interventional studies, 120 across the 3 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 24 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Lishu Gao as lead sponsor.
Lishu Gao has 1 study filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
6 of the studies in Generalized Anxiety Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07640945Central South UniversityMRI-Guided Accelerated cTBS for Generalized Anxiety Disorder | 2027-01 |
| NCT07330648Anhui Medical UniversityProspective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder | 2027-01-31 |
| NCT07403591Anhui Medical UniversityMapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder | 2027-03-01 |
| NCT07909200Central South UniversityTemporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder | 2027-03-01 |
| NCT07290153Fudan UniversityPsychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 24 studies in Generalized Anxiety Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the clinical efficacy and safety of electroacupuncture (EA) as an adjunctive treatment for generalized anxiety disorder (GAD). Participants in the clinical trial will be randomly assigned to an EA group, a sham EA group, or a waiting-list control group. All participants in the clinical trial will receive monotherapy with one of three SSRIs: sertraline, paroxetine, or escitalopram, selected by a psychiatrist according to clinical suitability, previous treatment response, and tolerability. Clinical efficacy will be assessed using the Hamilton Anxiety Rating Scale (HAMA). The neuroimaging substudy will include healthy controls and two groups of patients with GAD receiving SSRI monotherapy with an unchanged medication type and daily dose for at least 2 weeks: an EA group and a sham EA group. Healthy controls will undergo a single resting-state functional MRI (rs-fMRI) scan, whereas patients will undergo scans before and after a single 30-minute EA or sham EA session on the same day. Functional connectivity (FC), regional homogeneity (ReHo), and amplitude of low-frequency fluctuation (ALFF) will be compared between healthy controls and patients before intervention, and pre-to-post changes will be compared between the EA and sham EA groups.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive electroacupuncture in addition to SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist.
Procedure: Electroacupuncture (EA) · Drug: Medication
Participants will receive sham electroacupuncture in addition to SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist.
Procedure: Sham Electroacupuncture (SEA) · Drug: Medication
Participants will receive SSRI monotherapy with sertraline, paroxetine, or escitalopram, selected and managed by a psychiatrist, and will be offered delayed electroacupuncture according to the study protocol.
Drug: Medication
Electroacupuncture (EA) is performed at acupoints including GV20 (Baihui), EX-HN1 (Sishencong), GV29 (Shenting), EX-HN16 (Anmian, bilateral), HT7 (Shenmen, bilateral), PC6 (Neiguan, bilateral), CV6 (Qihai), CV4 (Guanyuan), ST36 (Zusanli, bilateral), SP6 (Sanyinjiao, bilateral), and LR3 (Taichong, bilateral). Sterile disposable needles (φ0.18×25mm or φ0.25×40mm) are used. Electric stimulation (continuous wave, 100Hz) is applied to specific point pairs (e.g., left Sishencong + anterior Sishencong) for 30 minutes. The current intensity is adjusted to the patient's maximum tolerance. Treatment is administered 3 times per week for 4 weeks (12 sessions total).
Sham electroacupuncture (SEA) is performed by inserting needles into non-acupoints located 5-10 mm away from the real points used in the EA group. Shallow needling (depth of 1-2 mm) is applied. A sham EA device with a disconnected electrode lead is used; although the screen displays parameters identical to the EA group, there is no actual current output. The duration, frequency, and total number of sessions are identical to the EA group (3 times/week for 4 weeks).
Each participant will receive only one of the following SSRIs: sertraline, paroxetine, or escitalopram. Medication selection will be made by a psychiatrist before randomization. Dosing and dose adjustments will follow the prespecified medication management protocol, with the same rules applied across all three study groups. Any medication changes and their reasons will be recorded.
Effective rate of HAMA score reduction at Week 4
The percentage of participants who achieved a HAMA score reduction rate of ≥50% from baseline. HAMA scores are evaluated to categorize outcomes as recovered, markedly effective, effective, or ineffective.
Time frame: Week 4 (at the end of treatment)
Change from Baseline in Hamilton Anxiety Scale (HAMA) Scores
HAMA is used to assess the severity of anxiety symptoms. It contains 14 items, including somatic and psychic anxiety. Total scores range from 0 to 56, where higher scores indicate more severe anxiety
Time frame: Baseline, Week 2, Week 4, and Week 8
Change from Baseline in Zung Self-Rating Anxiety Scale (SAS) Scores
The SAS is a 20-item self-report scale assessing anxiety symptoms. Each item is scored from 1 to 4, with positively worded items reverse-scored. The total raw score ranges from 20 to 80 and is multiplied by 1.25 to obtain a standardized score ranging from 25 to 100. Higher scores indicate more severe anxiety. Changes from baseline will be assessed at Weeks 2, 4, and 8, with negative changes indicating improvement.
Time frame: Baseline, Week 2, Week 4, and Week 8.
Change from Baseline in Social Disability Screening Schedule (SDSS) Scores
SDSS is used to evaluate the daily functioning of patients. It consists of 10 items, with each item scored from 0 to 2. Higher total scores reflect a higher degree of social disability.
Time frame: Baseline, Week 2, Week 4, and Week 8
Frequency of Participants with Changes in medication Dosage
The study will record whether the daily dose of medication increased, remained unchanged, or decreased compared to the baseline.
Time frame: Week 2, Week 4, and Week 8
Changes in Functional Connectivity (FC), Regional Homogeneity (ReHo), and Amplitude of Low-Frequency Fluctuation (ALFF)
Resting-state fMRI will assess FC, ReHo, and ALFF in healthy controls during a single scan and in patients with GAD before and after a single 30-minute EA or sham EA session. Pre-intervention measures in patients will be compared with those in healthy controls, and pre-to-post changes will be compared between the EA and sham EA groups.
Time frame: Patients: before and after a single 30-minute EA or sham EA session, on the same day. Healthy controls: a single assessment.
Adverse Events
Adverse events such as bleeding, haematoma, or unbearable pain caused by the needle, as well as drug-induced nausea, vomiting or dizziness, will all be recorded.
Time frame: Up to week 8
Acupuncture Treatment Adherence
At the end of the 4-week intervention, treatment adherence will be assessed in the electroacupuncture and sham electroacupuncture groups. The adherence rate will be calculated for each participant as the number of treatment sessions attended divided by the total number of scheduled sessions (12), multiplied by 100%. Higher percentages indicate better adherence.
Time frame: Week 4 (at the end of treatment)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.
Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 19 months is below that.
Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →